Skip to main content

Table 1 Participant characteristicsa

From: Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis

  RA (n = 166) Control (n = 90) P-value
Median age (IQR), yr 54 (45 to 63) 53 (44 to 60) 0.38
Caucasian race, n (%) 147 (89) 77 (86) 0.55
Female sex, n (%) 114 (69) 56 (62) 0.30
RF-positive, n (%) 114 (72)
Median DAS28-ESR (IQR) 3.86 (2.63–4.90)
Median DAS28-CRP (IQR) 3.09 (2.06–3.80)
Tender joints, n (IQR) 2 (0 to 7)
Swollen joints, n (IQR) 3 (0 to 8)
Median CRP (IQR), mg/L 4.0 (1.2 to 11) 0.5 (0.2 to 1.5) <0.001
Median ESR (IQR), mm/hr 15 (7 to 36)
Known CAD, n (%) 17 (10) 9 (10) 0.95
Coronary artery calcium, n (%) 83 (52) 34 (39) 0.05
Coronary calcium score, Agatston units 2.7 (0 to 178.7) 0 (0 to 19.2) 0.02
Methotrexate use, n (%) 118 (71)
Leflunomide use, n (%) 29 (18)
Hydroxychloroquine use, n (%) 42 (25)
Anti-TNFα agent use, n (%) 33 (20)
Prednisone use, n (%) 89 (54)
NSAID use, n (%) 55 (33) 33 (37) 0.53
  1. aRF data were available in 159 patients with RA. Coronary artery calcium scores were available for 161 patients with RA and 88 control subjects. CAD, Coronary artery disease; CRP, High-sensitivity C-reactive protein; DAS28, Disease Activity Score based on 28 joints; ESR, Erythrocyte sedimentation rate; IQR, Interquartile range; NSAID, Non-steroidal anti-inflammatory drug; RA, Rheumatoid arthritis; RF, Rheumatoid factor; TNFα, Tumor necrosis factor α